Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 216

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation

Open access
Wallentin, Lars, Lopes, Renato D., Hanna, Michael, Thomas, Laine, Hellkamp, Anne, Nepal, Sunil, Hylek, Elaine M., Al-Khatib, Sana M., Alexander, John H., Alings, Marco, Amerena, John, Ansell, Jack, Aylward, Philip, Bartunek, Jozef, Commerford, Patrick, De Caterina, Raffaele, Erol, Cetin, Harjola, Veli-Pekka, Held, Claes, Horowitz, John D., Huber, Kurt, Husted, Steen, Keltai, Matyas, Lanas, Fernando, Lisheng, Liu, McMurray, John J.V., Oh, Byung-Hee, Rosenqvist, Mårten, Ruzyllo, Witold, Steg, Philippe Gabriel, Vinereanu, Dragos, Xavier, Denis, Granger, Christopher B. · 2013 · Circulation

Abstract

Background—: In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced stroke and systemic embolism, major bleeding, and mortality. We evaluated treatment effects in relation to 2 predictions of time in therapeutic range (TTR). Methods and Results—: The trial randomized 18 201 patients with atrial fibrillation to apixaban 5 mg twice daily or warfarin for at least 12 months. For each patient, a center average TTR was estimated with the use of a linear mixed model on the basis of the real TTRs in its warfarin-treated patients, with a fixed effect for country and random effect for center. For each patient, an individual TTR was also predicted with the use of a linear mixed effects model including patient characteristics as well. Median center average TTR was 66% (interquartile limits, 61% and 71%). Rates of stroke or systemic embolism, major bleeding, and mortality were consistently lower with apixaban than with warfarin across center average TTR and individual TTR quartiles. In the lowest and highest center average TTR quartiles, hazard ratios for stroke or systemic embolism were 0.73 (95% confidence interval [CI], 0.53–1.00) and 0.88 (95% CI, 0.57–1.35) ( P interaction =0.078), for mortality were 0.91 (95% CI, 0.74–1.13) and 0.91 (95% CI, 0.71–1.16) ( P interaction =0.34), and for major bleeding were 0.50 (95% CI, 0.36–0.70) and 0.75 (95% CI, 0.58–0.97) ( P interaction =0.095), respectively. Similar results were seen for quartiles of individual TTR. Conclusions—: The benefits of apixaban compared with warfarin for stroke or systemic embolism, bleeding, and mortality appear similar across the range of centers’ and patients’ predicted quality of international normalized ratio control. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00412984.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.112.142158

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 216

Metadata

Authors
Wallentin, L., Lopes, R. D., Hanna, M., Thomas, L., Hellkamp, A., Nepal, S., Hylek, E. M., Al-Khatib, S. M., Alexander, J. H., Alings, M., Amerena, J., Ansell, J., Aylward, P., Bartunek, J., Commerford, P., De Caterina, R., Erol, C., Harjola, V.-P., Held, C., Horowitz, J. D., Huber, K., Husted, S., Keltai, M., Lanas, F., Lisheng, L., McMurray, J. J. V., Oh, B.-H., Rosenqvist, M., Ruzyllo, W., Steg, P. G., Vinereanu, D., Xavier, D., & Granger, C. B.
Venue
Circulation
Published
2013-06-04
Volume
127
Issue
22
Pages
2166-2176
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2031654814
Cited by
216
References
5
FWCI
22.03
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation. https://app.cochat.ai/papers/10.1161/circulationaha.112.142158
The paper
Wallentin, L., Lopes, R. D., Hanna, M., Thomas, L., Hellkamp, A., Nepal, S., Hylek, E. M., Al-Khatib, S. M., Alexander, J. H., Alings, M., Amerena, J., Ansell, J., Aylward, P., Bartunek, J., Commerford, P., De Caterina, R., Erol, C., Harjola, V.-P., Held, C., . . . Granger, C. B. (2013). Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation. Circulation. https://doi.org/10.1161/circulationaha.112.142158

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.